会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • 핵산 전달용 세포내 환원성 폴리(올리고-아르기닌)
    • 用于核酸递送的细胞内可降低聚合物(OLIGO-ARGININE)
    • KR1020090120948A
    • 2009-11-25
    • KR1020080047011
    • 2008-05-21
    • 한양대학교 산학협력단
    • 김용희원영욱
    • C12N15/86C12N15/09
    • C12N15/87A61K47/6455C07K7/08C12N15/113
    • PURPOSE: A non-viral gene delivery system containing reducible poly(oligo-arginine) is provided to efficiently form stable complex with a gene and efficiently stabilize and transfect DNA. CONSTITUTION: A non-viral gene delivery vector contains a reducible poly(oligo-arginine). The reducible poly(oligo-arginine) is poly(oligo-D-arginine). The reducible poly(oligo-arginine) comprises cationic oligomer containing terminal cysteine which is crosslinked with disulfide. The reducible poly(oligo-arginine) comprises Cys-(D-R9)-Cys repeat unit. A gene delivery complex bind to a vector containing the reducible poly(oligo-arginine) with a delivery gene.
    • 目的:提供含有可还原性聚(寡聚精氨酸)的非病毒基因递送系统,以有效形成与基因的稳定复合物并有效稳定和转染DNA。 构成:非病毒基因递送载体含有可还原的聚(寡聚精氨酸)。 可还原的聚(寡聚精氨酸)是聚(寡聚-D-精氨酸)。 可还原的聚(寡精氨酸)包含与二硫化物交联的含有末端半胱氨酸的阳离子低聚物。 可还原的聚(寡聚精氨酸)包含Cys-(D-R9)-Cys重复单元。 基因递送复合物与含有可还原的聚(寡聚精氨酸)的载体与递送基因结合。
    • 2. 发明授权
    • 약물전달용 인체유래 재조합 젤라틴 나노입자
    • 用于药物递送的重组人凝乳酶纳米颗粒
    • KR100819184B1
    • 2008-04-04
    • KR1020070085751
    • 2007-08-24
    • 한양대학교 산학협력단
    • 김용희원영욱
    • A61K9/48A61K9/51B82Y5/00
    • A61K9/5169C07K2319/30Y10S514/951
    • A gene recombinant gelatin nano-particle is provided to minimize degeneration of bio-materials, have uniform molecular weight and release target ingredients continuously for a long time with minimum toxicity. A nano-particle includes a human derived gene recombinant gelatin prepared by crosslinking using genipin, wherein a drug is loaded into a space between gelatin chains and the size of the nano-particle is 50-300 nanometers. A method for preparing the gene recombinant gelatin nano-particle comprises the steps of: (a) mixing a drug to be delivered with the human derived gene recombinant gelatin; (b) adding ethanol to the mixture to desolvate; (c) adding genipin to the mixture in the ethanol to crosslink; and (d) evaporating the ethanol.
    • 提供基因重组明胶纳米颗粒以最小化生物材料的变性,具有均匀的分子量,长时间连续释放目标成分,毒性最小。 纳米颗粒包括通过使用京尼平进行交联制备的人源基因重组明胶,其中将药物加载到明胶链之间的空间中,并且纳米颗粒的尺寸为50-300纳米。 制备基因重组明胶纳米颗粒的方法包括以下步骤:(a)将待递送的药物与人源基因重组明胶混合; (b)向混合物中加入乙醇以使其脱水; (c)将乙腈加入乙醇中的混合物进行交联; 和(d)蒸发乙醇。
    • 6. 发明公开
    • 인체유래 젤라틴 복합체 및 이의 용도
    • 重组人类凝血因子及其用途
    • KR1020120080513A
    • 2012-07-17
    • KR1020110077670
    • 2011-08-04
    • 한양대학교 산학협력단
    • 김용희원영욱윤선미
    • A61K47/12A61K47/42A61K47/30A61K9/16
    • A61K47/62A61K47/42B82Y5/00
    • PURPOSE: A human gelatin conjugate is provided to enable sealing hydrophobic drugs into a hydrophotic core and to deliver an anticancer agent. CONSTITUTION: A human gelatin nano conjugate contains lipoic acid and recombinant gelatin of human genes which are chemically conjugated. The human gelatin nano conjugate contain alpha-tocopheryl succinic acid and the recombinant gelatin which are chemically conjugated. Themolecular weight of the recombinant gelatin is 8-100 kDa. A drug delivery system contains pharmaceutically active ingredients and nanoparticles. The pharmaceutically active ingredient is a hydrophobic drug such as doxorubicin, taxol, camptothecin, adriamycin, docetaxel, paclitaxel, cisplatin, mitomycin-C, porphyrinic derivative, chlorine derivative, gedanamycin derivative, 5-fluorouraciland 17-arylamino-17-desmethoxygeldanamycin, or alpha-tocopheryl succinic acid.
    • 目的:提供人类明胶缀合物,以将疏水性药物密封到疏水核心中并输送抗癌剂。 构成:人明胶纳米结合物含有硫辛酸和化学结合的人类基因重组明胶。 人明胶纳米结合物含有α-生育酚琥珀酸和化学偶联的重组明胶。 重组明胶的分子量为8-100kDa。 药物递送系统含有药物活性成分和纳米颗粒。 药物活性成分是疏水性药物,例如多柔比星,紫杉醇,喜树碱,阿霉素,多西他赛,紫杉醇,顺铂,丝裂霉素-C,卟啉衍生物,氯衍生物,格达霉素衍生物,5-氟尿嘧啶和17-芳基氨基-17-脱甲氧基格尔德霉素 生育酚琥珀酸。